Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04882150 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
NCT04882150 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 102 participants.
The verdict
NCT04882150, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety, tolerability, drug levels and drug effects of BMS-986196 in healthy participants. In addition, an evaluation of food and formulation effects on BMS-986196 absorption will be performed.
Interventions
- OTHER Placebo
- DRUG BMS-986196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2022-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04882150
The ClinicalTrials.gov registry entry for NCT04882150 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04882150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04882150 about?
NCT04882150 is a clinical study titled "A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants". The purpose of this study is to characterize the safety, tolerability, drug levels and drug effects of BMS-986196 in healthy participants. In addition, an evaluation of food and formulation effects on BMS-986196 absorption will be performed.
What is the current status of trial NCT04882150?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2021-05-27. Estimated completion is 2022-06-10.
What interventions are being tested in trial NCT04882150?
The interventions under investigation include: Placebo (OTHER), BMS-986196 (DRUG).
Who is sponsoring clinical trial NCT04882150?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.